We are pleased to announce that iPremom has been selected by the European Innovation Council under the EIC Accelerator program, one of Europe’s most competitive funding instruments supporting breakthrough deep-tech innovation.
This funding will enable us to accelerate the clinical validation and regulatory development of our molecular biomarker platform for early risk assessment of preeclampsia.
Preeclampsia affects approximately 5–8% of pregnancies worldwide and remains a leading cause of maternal and perinatal morbidity and mortality. Earlier identification of women at risk is critical to support personalized monitoring and improved clinical decision-making.
The EIC Accelerator evaluates scientific excellence, technological maturity, scalability, and implementation capacity through a rigorous multi-stage selection process. Being selected reflects the strength of our scientific foundation and our commitment to translational rigor.
We are now advancing through key validation and regulatory milestones as we work toward bringing evidence-based innovation into maternal healthcare practice.
We thank the European Innovation Council for its trust and our team for its dedication and scientific commitment.
